ArticleThe Lancet regional health. Europe2023
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial.
Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02869971 (Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- Pooled it
- Trial
- [Prostate artery embolization-2026 update : Technique, evidence, and role in the treatment of benign prostatic hyperplasia].Radiologie (Heidelberg, Germany) · 2026Review
- Evaluation of prostate artery embolization for benign prostatic hyperplasia.International urology and nephrology · 2026Article
- Review
- Prostatic Artery Embolization: A Contemporary Review of Efficacy, Safety, and Expanding Clinical Indications.Current urology reports · 2026Review
- Prostatic Artery Embolization Using Ethylene Vinyl Alcohol Copolymer (EVOH): Efficacy, Safety and Clinical Impact of Liquid Embolic Penetration.Cardiovascular and interventional radiology · 2026Article
- Management of lower urinary tract symptoms before prostate cancer radiotherapy: a call for innovative strategies.World journal of urology · 2026Review
- Current considerations in prostate artery embolisation.CVIR endovascular · 2026Article
- The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS.Prostate cancer and prostatic diseases · 2026Article
- Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80-250 cc: the hope trial outcome at 1 year.World journal of urology · 2026Article
- Efficacy and Tolerability Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia: A Random-Effects Network Meta-Analysis.The world journal of men's health · 2026Article
- Predictors of Treatment Failure, Second-Line Therapy Outcomes, and Patient Satisfaction after Prostatic Artery Embolization: A Retrospective Study in Benign Prostatic Hyperplasia.Urologia internationalis · 2026Article
- N-butyl cyanoacrylate glue application in prostate artery embolization for benign prostatic hyperplasia: a systematic review of safety and efficacy.CVIR endovascular · 2025Review
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Factors associated with medication adherence trajectory among patients treated with oral anticancer drugs: a multicentre cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Prostate artery EmbolisAtion Safety and efficacY: Preliminary and foLlow-Up urodynamic Studies (P-EASY PLUS).BJU international · 2025Article
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health.Current urology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient's symptoms improvement after PAE and medical treatment. Methods: A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) defined by International Prostatic Symptom Score (IPSS) > 11 and quality of life (QoL) > 3, and BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day). Randomisation was stratified by centre, IPSS and prostate volume with a minimisation procedure. The primary outcome was the 9-month IPSS change. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome. ClinicalTrials.gov Identifier: NCT02869971. Findings: Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups, respectively. The 9-month change of IPSS was -10.0 (95% confidence interval [CI]: -11.8 to -8.3) and -5.7 (95% CI: -7.5 to -3.8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (-4.4 [95% CI: -6.9 to -1.9], p = 0.0008). The IIEF-15 score change was 8.2 (95% CI: 2.9-13.5) and -2.8 (95% CI: -8.4 to 2.8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 9 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group, respectively. Interpretation: In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms benefit than CT up to 24 months. Funding: French Ministry of Health and a complementary grant from Merit Medical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.